IP Library Granted Patent US 12,296,313
Granted Patent B2
US 12,296,313 · App. 17/181,766 · Granted May 13, 2025

System and method for formulating medical treatment effluents

Inventors: Walter Riley Buchanan (Lenexa, KS); Grant William Forsee (Kansas City, MO)
Assignee: MILTON ROY, LLC
B01J19/088A61L2/14A61L2/18C02F1/46109B01J2219/0809B01J2219/0884B01J2219/0894C02F2303/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,296,313
App. No.
17/181,766
Granted
May 13, 2025
Kind
B2
Abstract

A system and method for formulating a medical treatment effluent by performing plasma reactions creating a plasma area in a gas adjacent to a liquid. An embodiment of the plasma reactor includes a housing with an internal reaction chamber, first and second inlet paths to the reaction chamber, and electrodes for producing an electric field. The system may optionally further include a pre-ionization electrode and pre-ionization electric field for pre-ionizing a feed gas prior to entry into a reaction chamber. The reactor uses plasma to ionize gas adjacent with the liquid. The ionized gas reacts with the liquid to form an effluent. Exemplary medical treatments include: immunization (immuno) therapy; wound treatment; cancer treatment; and disinfectant applications.

Claims (17)

1. A method of injecting ionic particles from a gas into a liquid with a reactor including first and second electrodes connected to a power source and configured for forming an electric field therebetween, the method comprising:

inserting said liquid into a reaction chamber of the reactor;

inserting a high-pressure flow of said gas into said reaction chamber at a positive pressure relative to a pressure of said liquid in said reaction chamber, wherein the positive pressure enables the high-pressure flow of said gas to enter adjacent to said liquid;

applying a series of voltage pulses between said first and second electrodes and thereby producing said electric field, wherein at least a portion of said electric field is positioned within said reaction chamber; and

adjusting a magnitude of said voltage pulses and thereby controlling a ratio of man-atomic ions to molecular ions, said electric field contacting said gas and said liquid within said reaction chamber; and said ionic particles from said gas being transferred into said liquid to form a medical treatment effluent comprising said liquid infused with dissolved gas.

2. The method of claim 1 , wherein said medical treatment effluent is usable for vaccinating patients.

3. The method of claim 1 , wherein said medical treatment effluent is configured for wound treatment consisting of one or more of: tissue closure; reepithelialization; and skin grafting.

4. The method of claim 1 , wherein said medical treatment effluent is configured for cancer treatment by injecting into patients' blood streams for blocking cancer cell growth at tumor sites.

5. The method of claim 1 , wherein said medical treatment effluent is usable for disinfecting applications.

6. The method of claim 1 wherein:

said gas comprises oxygen; and

said liquid comprises water.

7. The method of claim 6 , wherein:

said ionic particles from said gas being transferred into said liquid comprise ions from said oxygen being transferred into said water.

8. The method according to claim 1 , wherein the reactor further includes a pre-ionization electrode connected to said power source while dielectrically isolated from said first electrode and positioned outside the reaction chamber, the method further comprising:

applying a voltage between said pre-ionization electrode and said second electrode producing a pre-ionization electric field within said reactor and outside said reaction chamber; and

flowing said high-pressure flow of said gas through said pre-ionization electric field prior to entry into said reaction chamber, partially ionizing said gas prior to said entry into said reaction chamber.

Assignments (4)
CERTIFICATE OF CONVERSION Recorded Jan 2, 2024
From: MILTON ROY, LLC
To: MILTON ROY, LLC
Reel/Frame 066174/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2021
From: ION INJECT TECHNOLOGY LLC
To: MILTON ROY, LLC
Reel/Frame 057102/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2021
From: FORSEE, GRANT WILLIAM
To: ION INJECT TECHNOLOGY LLC
Reel/Frame 055863/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2021
From: BUCHANAN, WALTER RILEY
To: ION INJECT TECHNOLOGY LLC
Reel/Frame 055863/0671 →
Continuity (5)
Continuation In Part 16205844 · Nov 30, 2018
Continuation In Part 16027005 · Jul 3, 2018
Continuation In Part 15277093 · Sep 27, 2016
Provisional Application 62235750 · Oct 1, 2015
Related Publication 20210178355A1 · Jun 17, 2021
References Cited (110)
US 4283291A · Lowther · 1981 [cited by applicant]
US 4399016A · Tsukada · 1983 [cited by applicant]
US 5311419A · Shires · 1994 [cited by applicant]
US 5387842A · Roth et al. · 1995 [cited by applicant]
US 5399832A · Tanisaki et al. · 1995 [cited by applicant]
US 5414324A · Roth · 1995 [cited by applicant]
US 5872426A · Kunhardt et al. · 1999 [cited by applicant]
US 5900103A · Tomoyasu et al. · 1999 [cited by applicant]
US 5959412A · Ushijima · 1999 [cited by applicant]
US 6005349A · Khnhardt et al. · 1999 [cited by applicant]
US 6069539A · Sanders et al. · 2000 [cited by applicant]
US 6105518A · Robson et al. · 2000 [cited by applicant]
US 6118218A · Yializis et al. · 2000 [cited by applicant]
US 6147452A · Kunhardt et al. · 2000 [cited by applicant]
US 6167239A · Wright et al. · 2000 [cited by applicant]
US 6170668B1 · Babko-Malyi · 2001 [cited by applicant]
US 6208529B1 · Davidson · 2001 [cited by applicant]
US 6353846B1 · Fleeson · 2002 [cited by applicant]
US 6429400B1 · Sawada · 2002 [cited by applicant]
US 6433480B1 · Stark et al. · 2002 [cited by applicant]
US 6441553B1 · Yializis · 2002 [cited by applicant]
US 6489585B1 · Nakamura et al. · 2002 [cited by applicant]
US 6633109B2 · Falkenstein · 2003 [cited by applicant]
US 6664737B1 · Berry et al. · 2003 [cited by applicant]
US 6700787B1 · Beseth et al. · 2004 [cited by applicant]
US 6773335B2 · Yanobe et al. · 2004 [cited by applicant]
US 6818193B2 · Christodoulatos et al. · 2004 [cited by applicant]
US 6826222B2 · Hill · 2004 [cited by applicant]
US 6842122B1 · Langner et al. · 2005 [cited by applicant]
US 6853138B1 · Park et al. · 2005 [cited by applicant]
US 6946793B1 · Nelson · 2005 [cited by applicant]
US 6999022B1 · Vesel et al. · 2006 [cited by applicant]
US 7098420B2 · Crow et al. · 2006 [cited by applicant]
US 7215697B2 · Hill · 2007 [cited by applicant]
US 7221102B2 · Kotani et al. · 2007 [cited by applicant]
US 7273995B1 · Manz et al. · 2007 [cited by applicant]
US 7399944B2 · Devries et al. · 2008 [cited by applicant]
US 7507934B2 · Kondou et al. · 2009 [cited by applicant]
US 7737867B2 · Arthur et al. · 2010 [cited by applicant]
US 7764140B2 · Nagarkatti et al. · 2010 [cited by applicant]
US 7796954B2 · Whitaker Filho · 2010 [cited by applicant]
US 8081933B2 · Malaga et al. · 2011 [cited by applicant]
US 8089026B2 · Sellers · 2012 [cited by applicant]
US 8093758B2 · Hussman · 2012 [cited by applicant]
US 8254869B2 · Hyde et al. · 2012 [cited by applicant]
US 8542076B2 · Maier · 2013 [cited by applicant]
US 8633782B2 · Nagarkatti et al. · 2014 [cited by applicant]
US 8710926B2 · Nagarkatti et al. · 2014 [cited by applicant]
US 9106313B2 · Ueki · 2015 [cited by applicant]
US 9287800B2 · Hruska et al. · 2016 [cited by applicant]
US 9394189B2 · Hruska et al. · 2016 [cited by applicant]
US 9419581B2 · Mckinzie · 2016 [cited by applicant]
US 9420679B2 · Cheung et al. · 2016 [cited by applicant]
US 9573698B1 · He · 2017 [cited by applicant]
US 9665645B2 · Hawley · 2017 [cited by applicant]
US 9692392B2 · Cabanillas et al. · 2017 [cited by applicant]
US 9698748B2 · Manssen et al. · 2017 [cited by applicant]
US 9704405B2 · Kashi et al. · 2017 [cited by applicant]
US 9736920B2 · Smith et al. · 2017 [cited by applicant]
US 9819410B1 · Azevedo et al. · 2017 [cited by applicant]
US 20020000019A1 · Park et al. · 2002 [cited by applicant]
US 20030039297A1 · Wittle et al. · 2003 [cited by applicant]
US 20030049183A1 · Sharma et al. · 2003 [cited by applicant]
US 20030067273A1 · Benjamin et al. · 2003 [cited by applicant]
US 20040084382A1 · Ryazanova · 2004 [cited by applicant]
US 20040094401A1 · Carlow · 2004 [cited by applicant]
US 20040183461A1 · Kane et al. · 2004 [cited by applicant]
US 20040245087A1 · Lee · 2004 [cited by applicant]
US 20050260354A1 · Singh et al. · 2005 [cited by applicant]
US 20060097811A1 · Nakamura et al. · 2006 [cited by applicant]
US 20060150911A1 · Miyairi et al. · 2006 [cited by applicant]
US 20060208650A1 · Kondou · 2006 [cited by applicant]
US 20080060579A1 · Hsieh · 2008 [cited by applicant]
US 20080159925A1 · Shimizu et al. · 2008 [cited by applicant]
US 20080292497A1 · Vangeneugden et al. · 2008 [cited by applicant]
US 20090153279A1 · Chen · 2009 [cited by applicant]
US 20100123502A1 · Bhutta et al. · 2010 [cited by applicant]
US 20100171428A1 · Kirchmeier et al. · 2010 [cited by applicant]
US 20100219757A1 · Benzerrouk et al. · 2010 [cited by applicant]
US 20100310434A1 · Buchanan et al. · 2010 [cited by applicant]
US 20110241798A1 · Hong et al. · 2011 [cited by applicant]
US 20110284437A1 · Johnson et al. · 2011 [cited by applicant]
US 20120020844A1 · Foret et al. · 2012 [cited by applicant]
US 20120250370A1 · Taniguchi et al. · 2012 [cited by applicant]
US 20120262064A1 · Nagarkatti et al. · 2012 [cited by applicant]
US 20130194224A1 · Lai · 2013 [cited by applicant]
US 20140178604A1 · Selwyn · 2014 [cited by applicant]
US 20140246364A1 · Hruska · 2014 [cited by applicant]
US 20140246381A1 · Buchanan et al. · 2014 [cited by applicant]
US 20150022795A1 · Coenen et al. · 2015 [cited by applicant]
US 20150251933A1 · Nakamura · 2015 [cited by examiner]
US 20160028311A1 · Murakami · 2016 [cited by applicant]
US 20160030910A1 · Biberger et al. · 2016 [cited by applicant]
US 20160194224A1 · Buchanan et al. · 2016 [cited by applicant]
US 20160197564A1 · Buchanan et al. · 2016 [cited by applicant]
US 20170095788A1 · Buchanan · 2017 [cited by applicant]
US 20170312362A1 · Hybertson et al. · 2017 [cited by applicant]
US 20180050800A1 · Boykin et al. · 2018 [cited by applicant]
US 20180053501A1 · Hilal et al. · 2018 [cited by applicant]
US 20180302807A1 · Chen et al. · 2018 [cited by applicant]
US 20180311639A1 · Buchanan et al. · 2018 [cited by applicant]
US 20200027457A1 · Gelinske et al. · 2020 [cited by applicant]
US 20200082645A1 · Shaw et al. · 2020 [cited by applicant]
“International Search Report and Written Opinion”, International Application No. PCT/US2016/053919, Dec. 23, 2016. [cited by applicant]
“International Search Report and Written Opinion; PCT/US2019/0450473”. [cited by applicant]
“International Search Report and Writter Opinion”, PCT/US2014/016730, Jul. 4, 2015, pp. 1-18. [cited by applicant]
Schulz, et al., “Concentration fields near air-water interfaces during interfacial mass transport: oxygen transport and random square wave analysis”, Braz. J. Chem. Eng. vol. 26 No. 3 Sao Paulo Jul./Sep. 2009, Jul.-Sep.… [cited by applicant]
Extended European Search Report for European Patent Application No. 22205904.0 dated Aug. 4, 2023, 6 pages. [cited by applicant]
Communication Pursuant to Article 94(3) for European Application No. 19830254.9 dated Oct. 17, 2023, 6 pages. [cited by applicant]
Communication Pursuant to Article 94(3) for European Application No. 19830254.9 dated Jul. 4, 2024, 5 pages. [cited by applicant]